Table 4.
Association of clinicopathological features with lymph node metastasis of prostate cancer
| Variables | N | Lymph node metastasis | P value | |
|---|---|---|---|---|
| Negative | Positive | |||
| Total, n (%) | 279 | 184 | 95 | |
| Age (years) | ||||
| <70 | 136 (48.7) | 91 (49.5) | 45 (47.4) | .801 |
| ≧70 | 143 (51.3) | 93 (50.5) | 50 (52.6) | |
| BMI | ||||
| ≤25 | 142 (50.9) | 99 (53.8) | 43 (45.3) | .207 |
| >25 | 137 (49.1) | 85 (46.2) | 52 (54.7) | |
| Prostate volume (cm3) | ||||
| ≤35 | 99 (35.5) | 66 (35.9) | 33 (34.7) | .895 |
| >35 | 180 (64.5) | 118 (64.1) | 62 (65.3) | |
| Percentage of positive biopsies | ||||
| <50 | 176 (63.1) | 117 (63.6) | 59 (62.1) | .896 |
| ≥50 | 103 (36.9) | 67 (36.4) | 36 (37.9) | |
| PSA (ng/mL) | ||||
| <10 | 42 (15.1) | 34 (18.5) | 8 (8.4) | .015* |
| 10‐20 | 182 (65.2) | 121 (65.8) | 61 (64.2) | |
| >20 | 55 (19.7) | 29 (15.8) | 26 (27.4) | |
| PSAD (ng/mL·cm3) | ||||
| <0.15 | 18 (6.5) | 13 (7.1) | 5 (5.3) | .619 |
| ≥0.15 | 261 (93.5) | 171 (92.9) | 90 (94.7) | |
| Gleason score | ||||
| 2‐6 | 67 (36.4) | 67 (36.4) | 5 (5.3) | <.001* |
| 7 | 80 (43.5) | 80 (43.5) | 61 (64.2) | |
| 8‐10 | 66 (20.1) | 37 (20.1) | 29 (30.5) | |
| cT stage | ||||
| T1 | 42 (15.1) | 37 (20.1) | 5 (5.3) | .001* |
| T2 | 192 (68.8) | 124 (67.4) | 68 (71.5) | |
| T3 | 45 (16.1) | 23 (12.5) | 22 (23.2) | |
| Extracapsular extension | ||||
| Yes | 234 (83.9) | 161 (87.5) | 73 (76.8) | .026* |
| No | 45 (16.1) | 23 (12.5) | 22 (23.2) | |
| Seminal vesicle invasion | ||||
| Yes | 265 (95.0) | 179 (97.3) | 86 (90.5) | .020* |
| No | 14 (5.0) | 5 (2.7) | 9 (9.5) | |
| Positive surgical margin | ||||
| Yes | 246 (88.2) | 169 (91.8) | 77 (81.1) | .011* |
| No | 33 (11.8) | 15 (8.2) | 18 (18.9) | |
| LIMK1 expression | ||||
| − | 64 (22.9) | 60 (32.6) | 4 (4.2) | <.001* |
| + | 68 (24.4) | 51 (27.7) | 17 (17.9) | |
| ++ | 73 (26.2) | 41 (22.3) | 32 (33.7) | |
| +++ | 74 (26.5) | 32 (17.4) | 42 (44.2) | |
*
P < .05.